Alto Neuroscience (NYSE:ANRO) Shares Down 7.3% – Should You Sell?

Alto Neuroscience, Inc. (NYSE:ANRO) dropped 7.3% on Thursday . The stock traded as low as $31.86 and last traded at $31.5660. 540,236 shares were traded during mid-day trading, an increase of 41% from the average daily volume of 381,970 shares. The stock had previously closed at $34.07.

Wall Street Analysts Forecast Growth

ANRO has been the topic of several research reports. Wolfe Research began coverage on shares of Alto Neuroscience in a report on Friday, May 22nd. They issued an “outperform” rating on the stock. Zacks Research raised shares of Alto Neuroscience from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 20th. Wedbush upped their price target on shares of Alto Neuroscience from $24.00 to $26.00 and gave the stock a “neutral” rating in a research report on Thursday, August 13th. HC Wainwright raised their price objective on Alto Neuroscience from $50.00 to $55.00 and gave the company a “buy” rating in a research report on Monday, August 17th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Alto Neuroscience in a research note on Wednesday, July 29th. Eight equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $37.25.

Alto Neuroscience Price Performance

The business’s 50 day moving average price is $30.39 and its 200-day moving average price is $25.18. The company has a quick ratio of 14.85, a current ratio of 14.85 and a debt-to-equity ratio of 0.07. The company has a market cap of $1.23 billion, a PE ratio of -13.00 and a beta of 1.13.

Alto Neuroscience (NYSE:ANRO) last announced its earnings results on Wednesday, August 12th. The company reported ($0.65) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.08. As a group, analysts forecast that Alto Neuroscience, Inc. will post -2.68 earnings per share for the current year.

Institutional Trading of Alto Neuroscience

Several large investors have recently modified their holdings of ANRO. Invesco Ltd. acquired a new stake in Alto Neuroscience during the 1st quarter valued at approximately $67,000. AQR Capital Management LLC acquired a new stake in shares of Alto Neuroscience during the first quarter worth approximately $52,000. Marshall Wace LLP increased its stake in shares of Alto Neuroscience by 9.9% in the second quarter. Marshall Wace LLP now owns 937,407 shares of the company’s stock worth $2,062,000 after buying an additional 84,417 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of Alto Neuroscience in the second quarter worth $240,000. Finally, Bridgeway Capital Management LLC raised its holdings in Alto Neuroscience by 85.9% in the second quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock valued at $119,000 after acquiring an additional 25,000 shares in the last quarter.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.